Enaminones: Exploring additional therapeutic activities

Journal of Pharmaceutical Sciences

Volumn 96, Issue 10, 2007, Pages 2509-2531

  Edafiogho, Ivan O ^a   Kombian, Samuel B ^a   Ananthalakshmi, Kethireddy V V ^a   Salama, Noha N ^b   Eddington, Natalie D ^c   Wilson, Tiffany L ^d   Alexander, Mariano S ^e   Jackson, Patrice L ^e   Hanson, Clive D ^e   Scott, K R ^e  

^a KUWAIT UNIVERSITY   (Kuwait)

^b CAIRO UNIVERSITY   (Egypt)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^d ALBANY STATE UNIVERSITY   (United States)

^e HOWARD UNIVERSITY   (United States)

Author keywords

Blood brain barrier; Crystal structure; Efflux pumps; Log p; Molecular modeling; Multidrug resistance; P glycoprotein; PSAR

Indexed keywords

2,4 BIS(ALLYLAMINO) 6 [4 [[2,2 BIS(4 FLUOROPHENYL)ETHYL]AMINO]PIPERIDINO] 1,3,5 TRIAZINE; 5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; BENZYL[3 [[1 (3,4 DICHLOROPHENYL)ETHYL]AMINO] 2 HYDROXYPROPYL]PHOSPHINIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CALMODULIN INHIBITOR; CARBAMAZEPINE; CHLOROQUINE; CYCLOSPORIN A; ELACRIDAR; ENAMINE; ENAMINONE; ERYTHROMYCIN; FELBAMATE; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; NEUROLEPTIC AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; QUININE; QUINOLINE; RESERPINE; SDZPCS 833; STEROID; TAMOXIFEN; TARIQUIDAR; TOPIRAMATE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; ZOSUQUIDAR;

CELL FUNCTION; CRYSTAL STRUCTURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; GENE EXPRESSION; GENE INACTIVATION; HUMAN; MEDICAL RESEARCH; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACOGENOMICS; SHORT SURVEY; X RAY ANALYSIS;

EID: 35348976748     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20967     Document Type: Article

References (188)

1. Greenhill JV. 1977. Enaminones. Chem Soc Rev 6:277-294.
2. Elassar A-ZA, El-Khair AA. 2003. Recent developments in the chemistry of enaminones. Tetrahedron 59:8463-8480.
3. Huang Y, Hartmann RW. 1998. The improved preparation of 7,8-dihydroquinoline-5(6H)-one. Synthetic Comm 28:1197-1200.
4. Baraldi PG, Simoni D, Manfredini S. 1983. An improved reparation of enaminones from 1,3-diketones and ammonium acetate or amine acetates. Synthesis 1983:902-903.
5. Cartaya-Mann CP, Henderson DG, Soeder RW. 1997. Synthesis of enaminones using trimethylsilyl trifluoromethane sulfonate as an activator. Synthetic Comm 27:4275-4283.
6. Edafiogho IO, Alexander MS, Moore JA, Farrar VA, Scott KR. 1994. Anticonvulsant enaminones: With emphasis on methyl 4-[(p-chlorophenyl) amino]-6-methyl-2-oxocyclohex-3-en-1-oate (ADD 196022). Curr Med Chem 1:159-175.
7. Eddington ND, Cox DS, Roberts RR, Stables JP, Powell CB, Scott KR. 2000. Enaminones-versatile therapeutic pharmacophores. Further advances. Curr Med Chem 7:417-436.
8. Vogler B, Bayer R, Meller M, Kraus W. 1989. Photo-aza-Claisen rearrangements of cyclic enaminones. J Org Chem 54:4165-4168.
9. White JD, Ihle DC. 2006. Tandem photocycloaddition-retro-Mannich fragmentation of enaminones. A route to spiropyrrolines and the tetracyclic core of koumine. Org Lett 8:1081-1084.
10. Singh V, Saxena R, Batra S. 2005. Simple and efficient synthesis of substituted 2-pyrrolidinones, 2-pyrrolones, and pyrrolidines from enaminones of Baylis-Hillman derivatives of 3-isoxazolecarbaldehydes. J Org Chem 70:353-356.
11. Turunen BJ, Georg GI. 2006. Amino-acid derived enaminones: A study in ring formation providing valuable asymmetric synthons. J Am Chem Soc 128:8702-8703.
12. Wisniewski A Jr., Oliveira ARM, da Cunha CJ, Simonelli F, Marques FA. 1999. Synthesis of enaminones with stationary stereochemistry. J Braz Chem Soc 10:369-374.
13. Carson JR, Carmosin RJ, Pitis PM, Vaught JL, Almond HR, Stables JP, Wolf HH, Swinyard EA, White HS. 1997. Aroyl(aminoacyl)pyrroles, a new class of anticonvulsant agents. J Med Chem 40:1578-1584.
14. Foster JE, Nicholson JM, Butcher R, Stables JP, Edafiogho IO, Goodwin AM, Henson MC, Smith CA, Scott KR. 1999. Synthesis, characterization and anticonvulsant activity of enaminones. Part 6:Synthesis of substituted vinylic benzamides as potential anticonvulsants. Bioorg Med Chem 7:2415-2425.
15. Singh RK, Sinha N, Jain S, Salman M, Naqvi F, Anand N. 2005. A convenient and new approach to the synthesis of ω-heterocyclic amino acids from carboxy lactams through ring-chain-transformation. Part 2: Synthesis of (2R)-/(2S)-2-amino-methyl-3-(1-aryl-/1,5-diaryl-1H-pyrazol-3-yl)-propionic acid. Tetrahedron 61:8868-8874.
16. Back TG, Hamilton MD, Lim VJJ, Parvez M. 2005. Synthesis of the quinolizidine alkaloids (-)-lasubine II and (±)-myrtine by conjugate addition and intramolecular acylation of amino esters with acetylenic sulfones. J Org Chem 70:967-972.
17. Katritzky AR, Hayden AE, Kirichenko K, Pelphrey P, Ji Y. 2004. A novel route to imidoylbenzotriazoles and their application for the synthesis of enaminones. J Org Chem 69:5108-5111.
18. Abass M, Mostafa BB. 2005. Synthesis and evaluation of molluscicidal and larvicidal activities of some novel enaminones derived from 4- hydroxyquinolinones: Part IX. Bioorg Med Chem 13:6133-6144.
19. Davis FA, Zhang J, Li Y, Xu H, DeBrosse C. 2005. Asymmetric synthesis of 2,4,5-trisubstituted piperidines from sulfinimine-derived δ-amino β-ketoesters. Formal synthesis of pseudodistomin B triacetate. J Org Chem 70:5413-5419.
20. Kang J, Liang F, Sun S-G, Liu Q, Bi X-H. 2006. Copper-mediated C-N bond formation via direct aminolysis of dithioacetals. Org Lett 8:2547-2550.
21. Tanaka T, Mizuno T, Fukui S, Hiroaki H, Oku J-I, Kanaori K, Tajima K, Shirakawa M. 2004. Two-metal ion, Ni(II) and Cu(II), binding α-helical coiled coil peptide. J Am Chem Soc 126:14023-14028.
22. Tanaka F, Fuller R, Barbas CFIII. 2005. Development of small designer aldolase enzymes: Catalytic activity, folding and substrate specificity. Biochemistry 44:7583-7592.
23. Tanaka F, Fuller R. 2006. Control of function of a small peptide by a protein. Bioorg Med Chem Lett 16:4059-4062.
24. Hovinga CA. 2002. Novel anticonvulsant medications in development. Expert Opin Investig Drugs. 11:1387-1406.
25. Stables JP, Kupferberg HJ. 1997. The NIH anticonvulsant drug development (ADD) program: Preclinical anticonvulsant screening project. In: Avazini G, Tanganelli P, Avoli M, editors. Molecular and cellular targets for anti-epileptic drugs. London: John Libbey and Co. pp 191-198.
26. Richens A. 1991. New antiepileptic drugs. In: Pisani F, Perucca E, Avanzini G, Richens A, editors. New antiepileptic drugs. Amsterdam/New York: Elsevier. pp 89-96.
27. Schmidt D, Kramer G. 1994. The new anticonvulsant drugs. Implications for avoidance of adverse effects. Drug Saf 11:422-431.
28. Perucca E. 2000. New anti-epileptic drugs-fifth Eilat conference. 25-29 June 2000, Eilat, Israel. IDrugs 3:1149-1153.
29. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. 2001. Progress report on new antiepileptic drugs: A summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res 43:11-58.
30. Scott KR. Burger's medicinal chemistry and drug discovery. In: Abraham DJ, editor. New York: Wiley. 2003. Vol. 6: pp 264-328.
31. Anger T, Madge DJ, Mullah M, Riddell D. 2001. Medicinal chemistry of voltage-gated sodium channel blockers. J Med Chem 44:115-137.
32. Denac H, Mevissen M, Scholtysik G. 2000. Structure, function and pharmacology of voltage-gated sodium channels. Naunyn Schmiedebergs Arch Pharmacol 363:453-479.
33. Burack MA, Stasheff SF, Wilson WA. 1995. Selective suppression of in vitro electrographic seizures by low-dose tetrodotoxin: A novel anticonvulsant effect. Epilepsy Res 22:115-126.
34. Edafiogho IO, Hinko CN, Chang H, Moore JA, Mulzac D, Nicholson JM, Scott KR. 1992. Synthesis and anticonvulsant activity of enaminones. J Med Chem 35:2798-2805.
35. Scott KR, Edafiogho IO, Richardson EL, Farrar VA, Moore JA, Tietz EL, Hinko CN, Chang H, el-Assadi A, Nicholson JM. 1993. Synthesis and anticonvulsant activity of enaminones. 2. Further structure-activity correlations. J Med Chem 36:1947-1955.
36. Mulzac DM, Scott KR. 1993. Profile of anticonvulsant activity and minimal toxicity of methyl 4-[(p-chlorophenyl)amino]-6-methyl-2-oxo-cyclohex-3-en-1- oate and some prototype antiepileptic drugs in mice and rats. Epilepsia 34:1141-1146.
37. Edafiogho IO, Moore JA, Farrar VA, Nicholson JM, Scott KR. 1994. Nuclear magnetic resonance studies of anticonvulsant enaminones. J Pharm Sci 83:1155-1170.
38. Scott KR, Rankin GO, Stables JP, Alexander MS, Edafiogho IO, Farrar VA, Kolen KR, Moore JA, Sims LD, Tonnu AD. 1995. Synthesis and anticonvulsant activity of enaminones. 3. Investigations on 4′-, 3′-, and 2′-substituted and polysubstituted anilino compounds, sodium channel binding studies, and toxicity evaluations. J Med Chem 38:4033-4043.
39. Laws ML, Roberts RR, Nicholson JM, Butcher R, Stables JP, Goodwin AM, Smith CA, Scott KR. 1998. Synthesis, characterization, and anticonvulsant activity of enaminones. Part 5: Investigations on 3-carboalkoxy-2-methyl-2,3- dihydro-1H-phenothiazin-4[10H]-one derivatives. Bioorg Med Chem 6:2289-2299.
40. Eddington ND, Cox DS, Roberts RR, Butcher RJ, Stables JP, Edafiogho IO, Cooke N, Goodwin AM, Smith CA, Scott KR. 2002. Synthesis and anticonvulsant activity of enaminones. 4. Investigations on isoxazole derivatives. Eur J Med Chem 37:635-648.
41. Eddington ND, Cox DS, Khurana M, Salama NN, Stables JP, Harrison SJ, Negussie E, Taylor RS, Tran UQ, Moore JA, Barrow JC, Scott KR. 2003. Synthesis and anticonvulsant activity of enaminones. Part 7. Synthesis and anticonvulsant evaluation of ethyl 4-[(substituted phenyl)amino]-6-methyl-2-oxocyclohex-3-ene carboxylates and their corresponding 5-methylcyclohex-2-enone derivatives. Eur J Med Chem 38:49-64.
42. Salama NN, Eddington ND, Payne D, Wilson TL, Scott KR. 2004. Multidrug resistance and anticonvulsants: New studies with some enaminones. Curr Med Chem 11:2093-2113.
43. Anderson AJ, Nicholson JM, Bakare O, Butcher RJ, Wilson TL, Scott KR. 2006. Enaminones 9. Further studies on the anticonvulsant activity and potential type IV phosphodiesterase inhibitory activity of substituted vinylic benzamides. Bioorg Med Chem 14:997-1006.
44. Wilson TL, Jackson PL, Hanson CD, Xue Z, Eddington ND, Scott KR. 2005. QSAR of the anticonvulsant enaminones; molecular modeling aspects and other assessments. Med Chem 1:371-381.
45. Edafiogho IO, Ananthalakshmi KW, Kombian SB. 2006. Anticonvulsant evaluation and mechanism of action of benzylamino enaminones. Bioorg Med Chem 14:5266-5272.
46. Hogenkamp DJ, Johnstone TB, Gee KW. 2005. Substituted enaminones, their derivative and uses thereof. WO 108347.
47. McNamara JO. 1999. Emerging insights into the genesis of epilepsy. Nature 399:A15-A22.
48. McNamara JO. Identification of genetic defect of an epilepsy: Strategies for therapeutic advances. Epilepsia 1994. 35:S51-S57.
49. Dengledine R, McBain CJ, McNamara JO. 1990. Excitatory amino acid receptors in epilepsy. Trends Pharmacol Sci 11:334-338.
50. Khurana M, Salama NN, Scott KR, Nemieboka NN, Bauer KS Jr., Eddington ND. 2003. Preclinical evaluation of the pharmacokinetics, brain uptake and metabolism of E121, an antiepileptic enaminone ester, in rats. Biopharm Drug Dispos 24:397-407.
51. Kombian SB, Edafiogho IO, Ananthalakshmi W. 2005. Anticonvulsant enaminones depress excitatory synaptic transmission in the rat brain by enhancing extracellular GABA levels. Brit J Pharmacol 145:945-953.
52. + channels: Local anesthetics, anti-arrhythmics, and anticonvulsants. Trends Pharmacol Sci 8:57-65.52; (b) Willow M, Kuenzel EA, Catterall WA. 1984. Inhibition of voltage-sensitive sodium channels in neuroblasoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol 25:228-234.
53. 3H]-batrachotoxinin A 20-α-benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol 22:627-635.
54. Cheung H, Kamp D, Harris E. 1992. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res 13:107-112.
55. 2+ of NMDA responses in spinal cord neurons. Nature 309:261-263.
56. Edafiogho IO, Denny BJ, Schwalbe CH, Low PR. 2003. X-ray crystallographic and theoretical studies of an anticonvulsant enaminone: Methyl 4-(4′-bromophenyl)-amino-6-methyl-2-oxocyclohex-3-en-1-oate. Med Princ Pract 12:237-242.
57. B receptors. Trends Pharmacol Sci 14:259-261.
58. B receptors. Pharmacol Ther 67:187-246.
59. Soudijn W, van Wijingaarden I. 2000. The GABA transporter and its inhibitors. Curr Med Chem 7:1063-1079.
60. Löscher W, Horstermann D. 1994. Differential effects of vigabatrin, gamma-acetylenic GABA, aminooxyacetic acid, and valproate on levels of various amino acids in rat brain regions and plasma. Naunyn Schmiederberg's Arch Pharmacol 349:270-278.
61. Kombian SB, Edafiogho IO, Ananthalakshmi KVV. 2006. Enaminones and norepinephrine employ convergent mechanisms to modulate excitatory synaptic transmission in rat nucleus accumbens in vitro. Eur J Neurosci 141:345-356.
62. Ananthalakshmi KW, Edafiogho IO, Kombian SB. 2006. Concentration- dependent effects of anticonvulsant enaminone methyl 4-(4′-bromo-phenyl) aminocyclohex-3-en-6-methyl-2-oxo-1-oate on rat neuronal excitability in vitro. Neuroscience 141:345-356.
63. Pauling L. 1961. A molecular theory of general anesthesia. Science 134:15-21.
64. Pauling L. 1964. The hydrate microcrystal theory of general anesthesia. Anesth Analg 43:1-10.
65. Pauling L. 1964. Hydrate-microcrystal-theory of anesthesia. Anaesthesist 13:245-250.
66. 3. Acta Cryst C49:2045-2046.
67. Kubicki M, Bassyouni HAR, Codding PW. 2000. Hydrogen bonding in three anticonvulsant enaminones. J Mol Struct 525:141-152.
68. Scott KR, Butcher RJ, Hanson CD. 2006. 5,5-Dimethyl-3-(5-methylisoxazol- 3-yl)-cyclohex-2-enone. Acta Cryst F62:o218-o220.
69. Löscher W. 2002. Current status and future directions in the pharmacotherapy of epilepsy. Trends Pharmacol Sci 23:113-118.
70. Marroni M, Marchi N, Cucullo L, Abbott NJ, Signorelli K, Janigro D. 2003. Vascular and parenchymal mechanism in multiple drug resistance: A lesson from human epilepsy. Curr Drug Targets 4:297-304.
71. Abbott NJ, Khan EU, Rollinson CM, Reichel A, Janigro D, Dombrowski SM, Dobbie MS, Begley DJ. 2002. Drug resistance in epilepsy: The role of the blood-brain barrier. Novartis Found Symp 243:38-47 ; discussion 47-55, 180-185.
72. Awasthi S, Hallene HL, Fazio V, Singhal SS, Cucullo L, Awasthi YC, Dini G, Janigro D. 2005. RLIP76, a non-ABC transporter, and drug resistance in epilepsy. BMC Neurosci 6:61.
73. Sisodiya SM. 2003. Mechanisms of antiepileptic drug resistance. Curr Opin Neurol 16:197-201.
74. Potschka H, Fedrowitz M, Löscher W. 2003. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 306:124-131.
75. Potschka H, Löscher W. 2001. In vivo evidence for P-glycoprotein mediated transport of phenytoin at the blood brain barrier. Epilepsia 42:1231-1240.
76. Frey HH, Löscher W. 1978. Distribution of valproate across the interface between blood and cerebrospinal fluid. Neuropharmacology 17:637-642.
77. Potschka H, Fedrowitz M, Löscher W. 2001. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 12:3557-3560.
78. Kwan P, Brodie MJ. 2005. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 46:224-235.
79. Ishikawa T, Hirano H, Onishi Y, Sakurai A, Tarui S. 2004. Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: High-speed screening and structure-activity relationship analyses. Drug Metab Pharmacokinet 19:1-14.
80. Gottesman MM, Fojo T, Bates SE. 2002. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2:48-58.
81. Suzuki H, Sugiyama Y. 2000. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci 12:3-12.
82. Aungst BJ. 199. P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. Adv Drug Deliv Rev 39:105-116.
83. Deuchars K, Ling V. 1989. P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol 16:156-165.
84. Chiou WL, Chung SM, Wu TC. 2000. Commentary: Potential role of P-glycoprotein in affecting hepatic metabolism of drugs. Pharm Res 17:901-903.
85. Ekins S, Kim RB, Leake BF, Dantzig AH, Scheutz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wekel JH, Wrighton SA. 2002. Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol 61:964-973.
86. Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B. 2003. The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett 140-141:133-143.
87. Gottesman MM, Pastan I. 1993. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427.
88. Löscher W, Potschka H. 2005. Drug resistance in brain diseases and the role of drug efflux transporters. Nature Rev Neurosci 6:591-602.
89. Bialecka M, Hnatszyn G, Bielicka-Cymerman J, Drozdzik M. 2005. The effect of MDR1 gene polymorphism in the pathogenesis and the treatment of drug-resistant epilepsy. Neurol Neurochir Pol 39:476-181.
90. Potschka H, Fedrowitz M, Löscher W. 2002. P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier; evidence from microdialysis experiments in rats. Neurosci Lett 327:173-176.
91. Rizzi M, Caccia S, Guiso G, Richichi C, Gorter JA, Aronica E, Aliprandi M, Bagnati R, Fanelli R, D'Incalci M, Samanin R, Vezzani A. 2002. Limbic seizures induce P-glycoprotein in rodent brain: Functional implications for pharmacoresistance. J Neurosci 22:5833-5839.
92. Wacher VJ, Wu CY, Benet LZ. 1995. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and p-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
93. Benet LZ, Wu CY, Hebert MF, Wacher VJ. 1996. Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. J Contr Rel 39:139-143.
94. Wacher VJ, Silverman JA, Zhang Y, Benet LZ. 1998. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 87:1322-1330.
95. Zhang Y, Benet LZ. 2001. The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and p-glycoprotein. Clin Pharmacokinet 40:159-168.
96. Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, Mayo RR, Turgeon DK, Bailey DG, Fontana RJ, Wrighton SA. 1999. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 27:161-166.
97. Schuetz EG, Beck WT, Scheutz JD. 1996. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311-318.
98. Trunheim K. 2004. Drug interactions with anti-epileptic agents. Wien Klin Wochenschr 116:112-118.
99. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. 2000. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478.
100. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB. 1997. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62:248-260.
101. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijen JH, van Tellingen O. 1997. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035.
102. Kim RB, Leake BF, Zhou S, Lan LB, Scheutz JD, Schuetz EG, Wilkinson GR. 2001. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189-199.
103. Fururno T, Landi MT, Ceroni M, Caporaso N, Bernucci I, Nappi G, Martignoni E, Schaeffeler E, Eichelbaum M, Schwab M, Zanger UM. 2002. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 12:529-534.
104. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW, Sisodiya SM. 2003. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene AB CB1. N Engl J Med 348:1442-1448.
105. Yamauchi A, Ieiri I, Kataoka Y, Tanabe M, Nichizaki T, Oishi R, Higuchi S, Otsubo K, Sugimachi K. 2002. Neurotoxicity induced by tacrolimus after liver transplantation: Relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 74:571-572.
106. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. 1995. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin . J Clin Invest 96:1698-1705.
107. Saito S, Iida A, Sekine A, Miura Y, Ogawa C, Kawauchi S, Higuchi S, Nakamura Y. 2002. Three hundred twenty-six genetic variations in genes encoding nine members of ATP-bind cassette subfamily F ABCB/MDR/TAP, in the Japanese population. J Hum Genet 47:38-50.
108. Schwab M, Eichelbaum M, Fromm MF. 2003. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 43:285-307.
109. Evans WE, McLeod HL. 2003. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348:538-539.
110. Weinshilboum R. 2003. Inheritance and drug response. N Engl J Med 348:529-537.
111. Itoda M, Saito Y, Komamura K, Ueno K, Kamakura S, Ozawa S, Sawada J. 2002. Twelve novel single nucleotide polymorphisms in ABCB1/MDR1 among Japanese patients with ventricular tachycardia who were administered amiodarone. Drug Metab Pharmacokinet 17:566-571.
112. Pauli-Magnus C, Kroetz DL. 2004. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res 21:904-913.
113. Brant SR, Panhuysen CI, Nicolae D, Reddy DM, Bonen DK, Karaliukas R, Zhang L, Swanson E, Datta LW, Moran T, Ravenhill G, Duerr RH, Achkar JP, Karban AS, Cho JH. 2003. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet 73:1282-1292.
114. Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Seisell C, Hoffmeyer S, Kerb R, Fromm MR, Brinkmann U, Eichelbaum, Brockmoller J, Cascorbi I, Roots I. 2002. Modulation of steady state kinetics of digoxin by haplotypes of the P glycoprotein MDR1 gene. Clin Pharmacol Ther 72:574-594.
115. Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B, Beaune P, Legrendre C, Thevet E. 2003. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephro 114:1889-1892.
116. Goto M, Masuda S, Saito H, Uemoto S, Kiuchi T, Tanaka K, Inui K. 2002. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 12:451-157.
117. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, Freund D, Schakel U, Ehninger G, Schaich M. 2002. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 62:4955-4962.
118. Bonhomme-Faivre L, Devocelle A, Saliba F, Chatled S, Maccario J, Farinotti R, Picard B. 2004. MDR-1 C3435T polymorphism influences cyclosporine A dose requirement in liver-transplant recipients. Transplantation 78:21-25.
119. Marzolini C, Paus E, Buclin T, Kim RB. 2004. Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther 75:13-33.
120. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, Lee CG. 2002. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in thee ethnic Asian populations. Pharmacogentetics 4:397-410.
121. Sakaeda T, Nakamura T, Okumura K. 2003. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4:397-410.
122. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, Matsuo M, Kasura M, Okumura K. 2002. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 71:297-303.
123. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K. 2002. Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of the multidrug resistance (MDR1) gene. J Pharmacol Exp Ther 297:1137-1143.
124. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A. 2002. Swiss cohort study. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. Lancet 359:30-36.
125. Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, Warzok R, Kroemer HK, Casorbi I. 2002. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 72:572-583.
126. Owen A, Goldring C, Morgan P, Chadwick D, Park BK, Pirmohamed M. 2005 Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br J Clin Pharmacol 59:365-370.
127. + natural killer cells. Pharmacogenetics 11:293-298.
128. Oselin K, Gerloff T, Mrozikiewicz PM, Pahkla R, Roots I. 2003. MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fund Clin Pharmacol 17:463-469.
129. + hematopoietic stem cells. Haematologica 87:564-568.
130. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, Morita Y, Tamura T, Aoyama N, Hirai M, Kasuga M, Okumura K. 2001. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects.
131. Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, Brundage R, Starr S, Spector SA. 2005. An MDR 1-3435variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 19:371-380.
132. Nasi M, Borghi V, Pinti M, Bellodi C, Lugli E, Maffei S, Troiano L, Richeldi L, Mussini C, Esposito R, Cossarizza A. 2003. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS 17:1696-1698.
133. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. 2001. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 47:1048-1052.
134. Gibbs JE, Thomas SA. 2002. The distribution of the anti-HIV drug, 2′,3′-dideoxycytidine (ddc), across the blood-brain and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors. J Neurochem 80:392-104.
135. Kurzawski M, Drozdzik M, Suchy J, Kurawski G, Bialecka M, Gornik W, Lubinski J. 2005. Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol 61:389-394.
136. Siesgsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, Fritz P, Burk O, Decker J, Alken P, Rothenpieler U, Kerb R, Hoffmeyer S, Brauch H. 2002. Association of the P-glycoprotein transporter MDR1 (C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 13:1847-1854.
137. Sills GJ, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson EA, Brodie MJ. 2005. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 46:643-647.
138. Tishler DM, Weinberg KR, Hinton DR, Barbaro N, Arnett GM, Raffel C. 1995. MDRR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36:1-6.
139. Lazarowski A, Sevlever G, Taratuto A, Massaro M, Rabinowicz A. 1999. Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. Ped Neurol 21:731-734.
140. Zimprich F, Sunder-Plassmann R, Strogmann E, Gleiss A, Dai-Bianco A, Zimprich A, Plumer S, Baumgartner C, Mannhalter C. 2004. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 63:1087-1089.
141. Tan NC, Heron SE, Scheffer IE, Pelekanos JT, McMahon JM, Vears DF, Mulley JC, Berkovic SF. 2004. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 63:1090-1092.
142. Cox DS, Scott KR, Gao H, Raje S, Eddington ND. 2001. Influence of multidrug resistance (MDR) proteins at the blood brain barrier on the transport and brain distribution of enaminone anticonvulsants. J Pharm Sci 90:1540-1552.
143. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesmann MM. 1999.
144. Ford JM. 1995. Modulators of multidrug resistance. Preclinical studies. Hematol Oncol Clin North Am 9:337-361.
145. Sarkadi B, Szakacs G, Varadi A. 2003. Multidrug resistance and drug metabolism http//www.sigmaaldridh.com/Area_of_Interest/Drug_Discovery/ Drug_Metabolism/Review_Article.html.
146. Krishna R, Mayer LD. 2000. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11:265-283.
147. Mi Q, Cui B, Silva GL, Lantvit D, Lim E, Chai H, You M, Hollingshead MG, Mayo JG, Kinghorn AD, Pezzuto JM. 2001. Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype. Cancer Res 61:4030-4037.
148. Litman T, Druley TE, Stein WD, Bates SE. 2001. From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58:931-959.
149. List AF, Kopecky KJ, Willman CL, Head DR., Persons DL, Slovak ML, Dorr R, Karanes C, Hynes HE, Doroshow JH, Shurafa M, Applebaum FR. 2001. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study. Blood 98:3212-3220.
150. Leslie EM, Deeley RG, Cole SPC. 2001. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters.
151. Polli JW, Jarrett JL, Studerberg SD, Humphreys JE, Dennis SW, Brouwer KR, Woolley JL. 1999. Role of P-glycoprotein on the CNS disposition of amprenavir (141 W94), an HIV protease inhibitor. Pharm Res 16:1206-1212.
152. Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. 1999. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 104:1441-1447.
153. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB. 2000. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28:655-660.
154. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294.
155. Summers MA, Moore JL, McAuley JW. 2004. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother 38:1631-1634.
156. van Vliet EA, van Schaik R, Edelbroek PM, Redeker S, Aronica E, Wadman WJ, Marchi N, Vezzani A, Gorter JA. 2006. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 47:672-680.
157. Pajeva IK, Wiese M. 1997. QSAR and molecular modeling of catamphiphilic drugs able to modulate multidrug resistance in tumors. QSAR 16:1-10.
158. Klopman G, Leming MS, Ramu A. 1997. Quantitative structure-activity relationship of multidrug resistance reversal agents. J Pharmacol Exp Ther 52:323-334.
159. Pearce HL, Safa AR, Bach NH, Winter MA, Cirtain MC, Beck WT. 1989. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci USA 86:5182-5183.
160. Ramu A, Ramu N. 1992. Reversal of multidrug resistance by phenothiazines and structurally related compounds. Cancer Chemother Pharmacol 30:165-173.
161. Pearce HL, Winter MA, Beck WT. 1990. Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance. Adv
162. Pajeva IK, Wiese M. 1998. Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: A comparative molecular field analysis study. J Med Chem 41:1815-1826.
163. Ecker G, Huber M, Schmid D, Chiba P. 1999. The importance of a nitrogen atom in modulators of multidrug resistance. Mol Pharmacol 56:791-796.
164. Tmej C, Chiba P, Huber M, Richter E, Hitzler M, Schaper K-J, Ecker G. 1998. A combined Hansch/free Wilson approach as predictive tool in QSAR studies on propafenone-type modulators of multidrug resistance. Arch Pharm (Weinheim) 331:233-240.
165. Bakken GA, Jurs PC. 2000. Classification of multidrug-resistance reversal agents using structure-based descriptors and linear discriminant analysis. J Med Chem 43:4534-4541.
166. Pajeva IK, Wiese M. 1998. A comparative molecular field analysis of propafenone-type modulators of cancer multidrug resistance. QSAR 17:301-312.
167. Schmid D, Ecker G, Kopp S, Hitzler M, Chiba P. 1999. Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements. Biochem Pharmacol 58:1447-1456.
168. Seelig A. 1998. How does P-glycoprotein recognize its substrates? Int J Clin Pharmacol Ther 36:50-54.
169. Neuhoff S, Langguth P, Dressler C, Anderson TB, Regardh CG, Spahn-Langguth H. 2000. Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: Drugs and analogs, stereoisomers and metabolites. Int J Clin Pharmacol Ther 38:168-179.
170. Cox DS, Scott KR, Gao H, Eddington ND. 2001. Effect of P-glycoprotein on the pharmacokinetics and tissue distribution of enaminone anticonvulsants: Analysis by population and physiological approaches. J Pharmacol Exp Ther 302:1096-1104.
171. Cox D, Gao H, Raje S, Scott K, Eddington N. 2001. Enhancing permeation of marker compounds and enaminone anticonvulsants across Caco-2 monolayers by modulating tight junctions using zonula occludens toxic. Eur J Pharm Biopharm 52:145-150.
172. Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN. 1990. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance. Cancer Res 50:1748-1756.
173. Ford JM, Prozialeck WC, Hait WN. 1989. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol 35:105-115.
174. Stein WC, Cardarelli C, Pastan I, Gottesman MM 1994. Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates. Mol Pharmacol 45:763-772.
175. Salama NN, Scott KR, Eddington ND. 2004. The influence of enaminones on the transport and oral bioavailability of P-glycoprotein substrate therapeutic agents. Int J Pharm 273:135-147.
176. Salama NN, Scott KR, Eddington ND. 2004. DM27, an enaminone, modifies the in vitro transport of antiviral therapeutic agents. Biopharm Drug Dispos 25:227-236.
177. Leung S, Bendayan R. 1999. Role of P-glycoprotein in the renal transport of dideoxynucleoside analog drugs. Can J Physiol Pharmacol 77:625-630.
178. Hsiu SL, Hou YC, Wang YH, Tsao CW, Su SF, Chao PD. 2002. Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats. Life Sci 72:227-235.
179. Erlichman C, Moore M, Thiessen J, Kerr IG, Walker S, Goodman P, Bjarnason G, De Angelis C, Bunting P. 1993. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 53:4837-4842.
180. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH, Bleehen NM. 1996. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14:610-618.
181. Pourtier-Manzanedo A, Didier AD, Muller CD, Loor F. SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells. 1992. Anticancer Drugs 3:419-425.
182. Sarris AH, Younes A, McLaughlin P, Moore D, Hagemeister F, Swan F, Rodriguez MA, Romaguera J, North L, Mansfield P, Callendar D, Mesina O, Cabanillas R. 1996. Cyclosporin A doe not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 14:233-239.
183. Bohme M, Buchler M, Muller M, Keppler D. 1993. Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett 333:193-196.
184. Fischer GA, Lum BL, Hausdorff J, Sikic BI. 1996. Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 32A:1082-1088.
185. Lum B, Gosland M. 1995. MDR expression in normal tissues: Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am 9:319-336.
186. Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, Uyeda RT, Moran EJ, Dixon R, Guns ES, Mayer LD. 2000. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res 60:2964-2972.
187. Shepard RL, Wintger MA, Hsaio SC, Pearce HL, Beck WT, Dantzig AH. 1998. Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein. Biochem Pharmacol 56:719-727.
188. Pennock G, Dalton W, Woeske W, Appleton C, Mosley K, Plezia P, Miller T, Salmon S. 1991. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 83:105-110.